Biotech spin­out grabs $46M round, jumps straight in­to PhI­II with a drug/de­vice com­bo for rare lung con­di­tion

The Ger­man aerosol ther­a­py com­pa­ny PARI Phar­ma­ceu­ti­cals is spin­ning out a Phase III ef­fort to de­vel­op a drug/de­vice com­bo that match­es an in­haled for­mu­la­tion of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.